Product Information
CETIRIZINE HCL 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0476 per EA under NDC 16571040110. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 26, 2009.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571040110
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CETIRIZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077829FDA Approved
8/26/2009
On Market Since
10/1/2009
Pharmacological Classes
Price Statistics
The NADAC for CETIRIZINE HCL 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 27.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0476 per EA |
|---|---|
| All-time high | $0.0858 (Nov 13, 2019) |
| All-time low | $0.0382 (Nov 20, 2024) |
| 52-week high | $0.0526 |
| 52-week low | $0.0472 |
| Median price | $0.0556 |
| Average price | $0.0566 |
| Largest weekly change | +48.6% (May 22, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cetirizine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CETIRIZINE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CETIRIZINE HCL 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0476 per EA (NDC 16571040110), effective Sep 30, 2026.
How has the price of CETIRIZINE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for CETIRIZINE HCL 5 MG TABLET has declined 27.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CETIRIZINE HCL 5 MG TABLET?
Since Nov 28, 2013, the NADAC for CETIRIZINE HCL 5 MG TABLET has ranged from a low of $0.0382 (Nov 20, 2024) to a high of $0.0858 (Nov 13, 2019), with a median of $0.0556 per EA.
Are there cheaper alternatives to CETIRIZINE HCL 5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CETIRIZINE HCL 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CETIRIZINE HCL 5 MG TABLET?
CETIRIZINE HCL 5 MG TABLET (NDC 16571040110) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.